Early Access to CNM-Au8 Given to Patients Ineligible for HEALEY Trial

Early Access to CNM-Au8 Given to Patients Ineligible for HEALEY Trial

307440

Early Access to CNM-Au8 Given to Patients Ineligible for HEALEY Trial

Clene, and its wholly owned subsidiary Clene Nanomedicine, have launched an expanded access program (EAP) in the U.S. to allow certain people with amyotrophic lateral sclerosis (ALS) to gain access to its experimental oral therapy CNM-Au8. Called CNMAu8.EAP02, the program will focus on patients who are not eligible to enroll in the HEALEY ALS Platform Trial (NCT04297683) — the first multi-regimen study in ALS — Clene announced in a press release. EAPs are meant to…

You must be logged in to read/download the full post.